Valuation: Novavax, Inc.

Market Cap 1.75B 31.08B 1.54B 1.45B 1.32B 2.48B 168B 2.5B 17.39B 6.74B 85.85B 6.58B 6.44B 276B P/E 2026 *
-17x
P/E 2027 * -47.4x
Enterprise Value 1.97B 34.96B 1.73B 1.63B 1.49B 2.79B 189B 2.81B 19.56B 7.58B 96.58B 7.41B 7.25B 310B EV / Sales 2026 *
5.29x
EV / Sales 2027 * 7.73x
Free-Float
93.03%
Yield 2026 *
-
Yield 2027 * -
1 day+1.23%
1 week+9.89%
Current month+18.50%
1 month+21.54%
3 months+21.15%
6 months+13.18%
Current year+58.15%
1 week 179.9
Extreme 179.9
190
1 month 156
Extreme 156
190
Current year 125
Extreme 125
204.88
1 year 115
Extreme 115
204.88
3 years 65.1
Extreme 65.1
390
5 years 65.1
Extreme 65.1
4,999.99
10 years 65.1
Extreme 65.1
6,550.1
Manager TitleAgeSince
Chief Executive Officer 59 22/01/2023
Director of Finance/CFO 60 15/08/2021
Chief Tech/Sci/R&D Officer - 31/12/2021
Director TitleAgeSince
Director/Board Member 73 05/08/2010
Director/Board Member 66 31/10/2018
Director/Board Member 60 15/06/2020
Change 5-day change 1-year change 3-year change Capi.($)
+1.23%+9.89% - - 1.75B
-0.14%+4.33%+9.00%+31.64% 47.97B
-1.69%+1.48%+50.57%+34.53% 44.5B
+2.56%+7.34%+366.69%+608.26% 43.93B
+0.24%+2.85%+10.67%+94.47% 41.03B
-0.62%-1.11%+4.65%+48.91% 29.85B
-0.28%+1.07%+24.58%+155.58% 17.27B
+3.37%+9.21%+8.32% - 15.34B
-0.46%+1.20%+26.90%+42.21% 15.3B
-2.21%-4.70% - - 14.82B
Average +0.20%+2.35%+62.67%+145.08% 30B
Weighted average by Cap. +0.11%+2.86%+79.67%+160.28%

Financials

2026 *2027 *
Net sales 373M 6.61B 327M 309M 282M 527M 35.75B 531M 3.7B 1.43B 18.26B 1.4B 1.37B 58.69B 266M 4.72B 234M 221M 201M 376M 25.51B 379M 2.64B 1.02B 13.03B 999M 978M 41.89B
Net income -108M -1.91B -94.37M -89.13M -81.23M -152M -10.31B -153M -1.07B -413M -5.27B -404M -395M -16.92B -37.93M -672M -33.28M -31.43M -28.65M -53.62M -3.64B -54M -376M -146M -1.86B -142M -139M -5.97B
Net Debt 219M 3.88B 192M 181M 165M 310M 20.99B 312M 2.17B 841M 10.72B 822M 804M 34.46B 303M 5.37B 266M 251M 229M 429M 29.06B 432M 3.01B 1.16B 14.85B 1.14B 1.11B 47.72B
Logo Novavax, Inc.
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
Employees
749
Date Price Change Volume
25/09/26 MX$189.00 +1.23% 22
24/09/26 MX$186.70 +0.38% 462
23/09/26 MX$186.00 0.00% 84
22/09/26 MX$186.00 +1.57% 22
21/09/26 MX$183.13 +6.48% 581
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
10.63USD
Average target price
14.00USD
Spread / Average Target
+31.72%

Quarterly revenue - Rate of surprise